Advanced three cell therapy products for veterinary use, secured GMP certification, and raised PLN 53 million to fund a new manufacturing facility, while maintaining a strong cash position and progressing toward commercialization despite ongoing net losses and no product revenue.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.